DEF 14A: Accolade, Inc. Announces Annual Meeting of Stockholders to be Held Virtually on August 6, 2024

Accolade, Inc. will hold its Annual Meeting of Stockholders virtually on August 6, 2024, to elect directors, approve executive compensation, and ratify the selection of KPMG LLP as the independent accounting firm.

Summary

• Accolade, Inc. is holding its Annual Meeting of Stockholders on August 6, 2024, as a virtual meeting.
• Stockholders will vote on the election of three directors to hold office until the 2027 Annual Meeting.
• They will also vote on the advisory approval of executive compensation and the ratification of KPMG LLP as the independent registered public accounting firm for the fiscal year ending February 28, 2025.
• The record date for the Annual Meeting is June 17, 2024.
• The proxy statement and annual report are available online.
• In fiscal year 2024, Accolade grew revenue to $414 million, increased annual recurring revenue bookings (ARR) by 20% to $86 million, and repurchased ~$77 million of Senior Convertible Notes.
• The company also expanded to more than 1,200 enterprise customers with more than 14 million lives under coverage.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with revenue growth, increased ARR, and expectations for positive operating cash flow. The CEO's letter expresses confidence and excitement about the future.

Positives

• Revenue grew to $414 million in fiscal year 2024.
• Annual recurring revenue bookings (ARR) increased by 20% to $86 million.
• The company repurchased approximately $77 million of its Senior Convertible Notes, strengthening the balance sheet.
• Accolade expanded its customer base to over 1,200 enterprises, covering more than 14 million lives.
• The company recorded approximately $100 million of direct to consumer revenue through PlushCare.
• Platform Connected Revenue doubled, indicating existing customers are adding more services.
• New partnerships with health plans are extending the reach of virtual care offerings.

Negatives

• The document does not explicitly state any negatives.

Risks

• The proxy statement contains forward-looking statements that involve substantial risks and uncertainties, as detailed in the company's filings with the SEC, including the Annual Report on Form 10-K for the year ended February 29, 2024.

Future Outlook

Accolade expects to achieve positive operating cash flow in the current fiscal year.

Management Comments

• Rajeev Singh, CEO, stated that Accolade is leading the way in closing the Physician Gap.
• He highlighted the company's focus on Physician-led Advocacy to address gaps in access, care coordination, health equity, and data connectivity.
• He expressed excitement about the opportunities ahead to change the way healthcare is experienced in the country.

Industry Context

Accolade is operating in the healthcare industry, which is experiencing tremendous innovation, including new medicines and treatments, and the explosion of the virtual care industry. The company is focused on addressing the Physician Gap, which is a pervasive issue in the healthcare system.

Comparison to Industry Standards

• The document does not contain specific comparisons to industry standards or comparable companies.

Stakeholder Impact

• Shareholders are asked to vote on key proposals that will shape the company's direction.
• Employees are part of a company that is striving to improve healthcare access and outcomes.
• Customers (employers) benefit from Accolade's services that aim to lower medical costs and improve employee health.
• Members (patients) gain access to better care coordination and navigation through the healthcare system.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will announce preliminary voting results at the Annual Meeting and publish final results in a Form 8-K.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Stockholders, Board of Directors, Executive Compensation, KPMG, Director Election, Accolade